Crossmark

Study protocol of the multi-centre, randomised controlled trial of the Frankfurt Early Intervention Programme A-FFIP versus early intervention as usual for toddlers and preschool children with Autism Spectrum Disorder (A-FFIP study)

Crossref DOI link: https://doi.org/10.1186/s13063-019-3881-7

Published Online: 2020-02-24

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kitzerow, Janina

Hackbusch, Matthes

Jensen, Katrin

Kieser, Meinhard

Noterdaeme, Michele

Fröhlich, Ulrike

Taurines, Regina

Geißler, Julia

Wolff, Nicole

Roessner, Veit

Bast, Nico

Teufel, Karoline

Kim, Ziyon

Freitag, Christine M. https://orcid.org/0000-0001-9676-4782
Funding

Funding for this research was provided by:

German Research Foundation (FR 2069/8-1)
License Information

Text and Data Mining valid from 2020-02-24

Version of Record valid from 2020-02-24
More Information

Article History

Received: 20 May 2019

Accepted: 4 November 2019

First Online: 24 February 2020

Ethics approval

: Ethical approval was granted from the Ethics Committee of the University Hospital Frankfurt on 4 April 2018 (ref. No.:10/18).

: Not applicable

: KT and CMF developed the A-FFIP approach and receive royalties for the A-FFIP manual. CMF receives additional royalties for other books on ASD, ADHD and MDD. She has served as consultant to Desitin and Roche during the last 3 years. VR has received payment for consulting and writing activities from Lilly, Novartis, and Shire Pharmaceuticals, lecture honoraria from Lilly, Novartis, Shire Pharmaceuticals, and Medice Pharma, and support for research from Shire Pharmaceuticals and Novartis. He has carried out (and is currently carrying out) clinical trials in cooperation with the Novartis, Shire, Servier and Otsuka companies. All other authors declare that they have no competing interests.

Document is current

Any future updates will be listed below